Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Chem Pharm Bull (Tokyo) ; 69(4): 360-373, 2021.
Article in English | MEDLINE | ID: mdl-33790081

ABSTRACT

The M3 muscarinic acetylcholine receptor (mAChR) plays an essential pharmacological role in mediating a broad range of actions of acetylcholine (ACh) released throughout the periphery and central nerve system (CNS). Nevertheless, its agonistic functions remain unclear due to the lack of available subtype-selective agonists or positive allosteric modulators (PAMs). In the course of our extended structure-activity relationships (SARs) study on 2-acylaminothiazole derivative 1, a previously reported PAM of the M3 mAChR, we successfully identified N-pyrimidyl/pyridyl-2-thiazolamine analogues as new scaffolds. The SARs study was rationalized using conformational analyses based on intramolecular interactions. A comprehensive study of a series of analogues described in this paper suggests that a unique sulfur-nitrogen nonbonding interaction in the N-pyrimidyl/pyridyl-2-thiazolamine moiety enable conformations that are essential for activity. Further, a SARs study around the N-pyrimidyl/pyridyl-2-thiazolamine core culminated in the discovery of compound 3g, which showed potent in vitro PAM activity for the M3 mAChR with excellent subtype selectivity. Compound 3g also showed a distinct pharmacological effect on isolated smooth muscle tissue from rat bladder and favorable pharmacokinetics profiles, suggesting its potential as a chemical tool for probing the M3 mAChR in further research.


Subject(s)
Allosteric Regulation/drug effects , Pyrimidines/chemistry , Pyrimidines/pharmacology , Receptor, Muscarinic M3/metabolism , Thiazoles/chemistry , Thiazoles/pharmacology , Amination , Animals , Drug Design , Female , Humans , Pyrimidines/chemical synthesis , Pyrimidines/pharmacokinetics , Rats , Rats, Sprague-Dawley , Structure-Activity Relationship , Thiazoles/chemical synthesis , Thiazoles/pharmacokinetics
2.
J Pharmacol Exp Ther ; 366(2): 390-396, 2018 08.
Article in English | MEDLINE | ID: mdl-29884626

ABSTRACT

Current pharmacotherapies for lower urinary tract symptoms associated with benign prostate hyperplasia (LUTS/BPH) are in need of improvement. Lysophosphatidic acid (LPA) is a phospholipid with various biologic functions. However, its exact role in the lower urinary tract and its target receptor subtype have not been fully elucidated. We investigated the role of LPA and the type 1 LPA receptor (LPA1) in urethral/prostatic contractile function and prostate cell proliferation by pharmacologically characterizing ASP6432 (potassium 1-(2-{[3,5-dimethoxy-4-methyl-N-(3-phenylpropyl)benzamido]methyl}-1,3-thiazole-4-carbonyl)-3-ethyl-2,2-dioxo-2λ6-diazathian-1-ide), a novel LPA1 antagonist. ASP6432 exhibited potent and selective antagonistic activity against LPA1 in cells expressing LPA receptor subtypes. In isolated rat tissue strips and anesthetized rats, ASP6432 concentration-/dose-dependently inhibited LPA-induced urethra and prostate contractions. In addition, in anesthetized rats, ASP6432 maximally decreased the urethral perfusion pressure (UPP) in the absence of exogenous LPA stimulation by 43% from baseline, whereas tamsulosin, an α1-adrenoceptor antagonist, reduced UPP by 22%. Further, in human prostate stromal cells, ASP6432 significantly and concentration-dependently suppressed LPA-induced bromodeoxyuridine incorporation. These results demonstrate a pivotal role for LPA and LPA1 in the regulation of urethral tonus and prostate cell proliferation. The potent urethral relaxation and inhibition of prostatic stromal cell growth indicate the potential of ASP6432 as a novel therapeutic agent for LUTS/BPH.


Subject(s)
Prostate/cytology , Prostate/drug effects , Receptors, Lysophosphatidic Acid/antagonists & inhibitors , Thiazoles/pharmacology , Urethra/drug effects , Urethra/physiology , Benzamides , Calcium/metabolism , Cell Proliferation/drug effects , Humans , Intracellular Space/drug effects , Intracellular Space/metabolism , Male , Muscle Contraction/drug effects , Prostate/physiology , Stromal Cells/cytology , Stromal Cells/drug effects
3.
Chem Pharm Bull (Tokyo) ; 53(4): 402-9, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15802840

ABSTRACT

A novel series of N-arylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic properties were evaluated. Reporter assays indicated that trans-2,5-dimethylpiperazine derivatives are potent AR antagonists, and in this series trans-N-4-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,4-difluorophenyl)-2,5-dimethylpiperazine-1-carboxamide (18 g, YM-175735) exhibited the most potent antiandrogenic activity. Compared to bicalutamide, YM-175735 is an approximately 4-fold stronger AR antagonist and has slightly increased antiandrogenic activity, suggesting that YM-175735 may be useful in the treatment of prostate cancer.


Subject(s)
Aminoimidazole Carboxamide/chemical synthesis , Aminoimidazole Carboxamide/pharmacology , Androgen Antagonists/chemical synthesis , Androgen Antagonists/pharmacology , Androgen Receptor Antagonists , Piperazines/chemical synthesis , Piperazines/pharmacology , Androgen Antagonists/therapeutic use , Animals , Indicators and Reagents , Magnetic Resonance Spectroscopy , Male , Mass Spectrometry , Orchiectomy , Piperazines/therapeutic use , Prostate/drug effects , Prostate/growth & development , Prostatic Neoplasms/drug therapy , Rats , Rats, Wistar , Testosterone/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...